| biotech vs life science: From Breakthrough to Blockbuster Donald L. Drakeman, Lisa N. Drakeman, Nektarios Oraiopoulos, 2022 Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. How could a large collection of small companies, most with fewer than 50 employees, compete in one of the world's most breathtakingly expensive and highly regulated industries? This book shows how biotech companies have met the challenge by creating nearly 40% more of the most important treatments for unmet medical needs. Moreover, they have done so with much lower overall costs. The book focuses on both the companies themselves and the broader biotech ecosystem that supports them. Its portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies shows how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions. Looking to the future, it concludes that biomedical research will continue to be most effective in the hands of a large group of small companies as long as national healthcare policies allow the rest of the ecosystem to continue to thrive-- |
| biotech vs life science: Intellectual Property Rights and the Life Science Industries Graham Dutfield, 2009 This book is a highly readable and entertaining account of the co-evolution of the patent system and the life science industries since the mid-19th century. The pharmaceutical industries have their origins in advances in synthetic chemistry and in natural products research. Both approaches to drug discovery and business have shaped patent law, as have the lobbying activities of the firms involved and their supporters in the legal profession. In turn, patent law has impacted on the life science industries. Compared to the first edition, which told this story for the first time, the present edition focuses more on specific businesses, products and technologies, including Bayer, Pfizer, GlaxoSmithKline, aspirin, penicillin, monoclonal antibodies and polymerase chain reaction. Another difference is that this second edition also looks into the future, addressing new areas such as systems biology, stem cell research, and synthetic biology, which promises to enable scientists to OC inventOCO life forms from scratch. |
| biotech vs life science: Gene Jockeys Nicolas Rasmussen, 2014-05-15 The scientific scramble to discover the first generation of drugs created through genetic engineering. The biotech arena emerged in the 1970s and 1980s, when molecular biology, one of the fastest-moving areas of basic science in the twentieth century, met the business world. Gene Jockeys is a detailed study of the biotech projects that led to five of the first ten recombinant DNA drugs to be approved for medical use in the United States: human insulin, human growth hormone, alpha interferon, erythropoietin, and tissue plasminogen activator. Drawing on corporate documents obtained from patent litigation, as well as interviews with the ambitious biologists who called themselves gene jockeys, historian Nicolas Rasmussen chronicles the remarkable, and often secretive, work of the scientists who built a new domain between academia and the drug industry in the pursuit of intellectual rewards and big payouts. In contrast to some who critique the rise of biotechnology, Rasmussen contends that biotech was not a swindle, even if the public did pay a very high price for the development of what began as public scientific resources. Within the biotech enterprise, the work of corporate scientists went well beyond what biologists had already accomplished within universities, and it accelerated the medical use of the new drugs by several years. In his technically detailed and readable narrative, Rasmussen focuses on the visible and often heavy hands that construct and maintain the markets in public goods like science. He looks closely at how science follows money, and vice versa, as researchers respond to the pressures and potential rewards of commercially viable innovations. In biotechnology, many of those engaged in crafting markets for genetically engineered drugs were biologists themselves who were in fact trying to do science. This book captures that heady, fleeting moment when a biologist could expect to do great science through the private sector and be rewarded with both wealth and scientific acclaim. |
| biotech vs life science: Calculations for Molecular Biology and Biotechnology Frank H. Stephenson, 2010-07-30 Calculations for Molecular Biology and Biotechnology: A Guide to Mathematics in the Laboratory, Second Edition, provides an introduction to the myriad of laboratory calculations used in molecular biology and biotechnology. The book begins by discussing the use of scientific notation and metric prefixes, which require the use of exponents and an understanding of significant digits. It explains the mathematics involved in making solutions; the characteristics of cell growth; the multiplicity of infection; and the quantification of nucleic acids. It includes chapters that deal with the mathematics involved in the use of radioisotopes in nucleic acid research; the synthesis of oligonucleotides; the polymerase chain reaction (PCR) method; and the development of recombinant DNA technology. Protein quantification and the assessment of protein activity are also discussed, along with the centrifugation method and applications of PCR in forensics and paternity testing. - Topics range from basic scientific notations to complex subjects like nucleic acid chemistry and recombinant DNA technology - Each chapter includes a brief explanation of the concept and covers necessary definitions, theory and rationale for each type of calculation - Recent applications of the procedures and computations in clinical, academic, industrial and basic research laboratories are cited throughout the text New to this Edition: - Updated and increased coverage of real time PCR and the mathematics used to measure gene expression - More sample problems in every chapter for readers to practice concepts |
| biotech vs life science: Biodefense in the Age of Synthetic Biology National Academies of Sciences, Engineering, and Medicine, Division on Earth and Life Studies, Board on Life Sciences, Board on Chemical Sciences and Technology, Committee on Strategies for Identifying and Addressing Potential Biodefense Vulnerabilities Posed by Synthetic Biology, 2019-01-05 Scientific advances over the past several decades have accelerated the ability to engineer existing organisms and to potentially create novel ones not found in nature. Synthetic biology, which collectively refers to concepts, approaches, and tools that enable the modification or creation of biological organisms, is being pursued overwhelmingly for beneficial purposes ranging from reducing the burden of disease to improving agricultural yields to remediating pollution. Although the contributions synthetic biology can make in these and other areas hold great promise, it is also possible to imagine malicious uses that could threaten U.S. citizens and military personnel. Making informed decisions about how to address such concerns requires a realistic assessment of the capabilities that could be misused. Biodefense in the Age of Synthetic Biology explores and envisions potential misuses of synthetic biology. This report develops a framework to guide an assessment of the security concerns related to advances in synthetic biology, assesses the levels of concern warranted for such advances, and identifies options that could help mitigate those concerns. |
| biotech vs life science: Career Opportunities in Biotechnology and Drug Development Toby Freedman, 2008 An essential guide for students in the life sciences, established researchers, and career counselors, this resource features discussions of job security, future trends, and potential career paths. Even those already working in the industry will find helpful information on how to take advantage of opportunities within their own companies and elsewhere. |
| biotech vs life science: Science and Security in a Post 9/11 World National Research Council, Policy and Global Affairs, Committee on Science, Technology, and Law, Committee on a New Government-University Partnership for Science and Security, 2007-10-10 Based on a series of regional meetings on university campuses with officials from the national security community and academic research institutions, this report identifies specific actions that should be taken to maintain a thriving scientific research environment in an era of heightened security concerns. Actions include maintaining the open exchange of scientific information, fostering a productive environment for international scholars in the U.S., reexamining federal definitions of sensitive but unclassified research, and reviewing policies on deemed export controls. The federal government should establish a standing entity, preferably a Science and Security Commission, that would review policies regarding the exchange of information and the participation of foreign-born scientists and students in research. |
| biotech vs life science: White Biotechnology Roland Ulber, Dieter Sell, 2007-01-30 With contributions by numerous experts |
| biotech vs life science: Pharmaceutical Biotechnology Gary Walsh, 2013-04-25 Pharmaceutical Biotechnology offers students taking Pharmacy and related Medical and Pharmaceutical courses a comprehensive introduction to the fast-moving area of biopharmaceuticals. With a particular focus on the subject taken from a pharmaceutical perspective, initial chapters offer a broad introduction to protein science and recombinant DNA technology- key areas that underpin the whole subject. Subsequent chapters focus upon the development, production and analysis of these substances. Finally the book moves on to explore the science, biotechnology and medical applications of specific biotech products categories. These include not only protein-based substances but also nucleic acid and cell-based products. introduces essential principles underlining modern biotechnology- recombinant DNA technology and protein science an invaluable introduction to this fast-moving subject aimed specifically at pharmacy and medical students includes specific ‘product category chapters’ focusing on the pharmaceutical, medical and therapeutic properties of numerous biopharmaceutical products. entire chapter devoted to the principles of genetic engineering and how these drugs are developed. includes numerous relevant case studies to enhance student understanding no prior knowledge of protein structure is assumed |
| biotech vs life science: Creating Life from Life Rosalyn W. Berne, 2014-12-19 This book is a collection of essays by scientists, historians, philosophers of science, and students. The essays meld biotechnology into science fiction stories and thereby open a conversation about the morality of what we may be one day, and what it may mean to be human as our biotechnological endeavors continue to evolve. The biotechnology revol |
| biotech vs life science: Biotechnology for Beginners Reinhard Renneberg, 2023-01-16 Biotechnology for Beginners, Third Edition presents the latest developments in the evolving field of biotechnology which has grown to such an extent over the past few years that increasing numbers of professional's work in areas that are directly impacted by the science. This book offers an exciting and colorful overview of biotechnology for professionals and students in a wide array of the life sciences, including genetics, immunology, biochemistry, agronomy and animal science. This book will also appeals to lay readers who do not have a scientific background but are interested in an entertaining and informative introduction to the key aspects of biotechnology. Authors Renneberg and Loroch discuss the opportunities and risks of individual technologies and provide historical data in easy-to-reference boxes, highlighting key topics. The book covers all major aspects of the field, from food biotechnology to enzymes, genetic engineering, viruses, antibodies, and vaccines, to environmental biotechnology, transgenic animals, analytical biotechnology, and the human genome. - Covers the whole of biotechnology - Presents an extremely accessible style, including lavish and humorous illustrations throughout - Includes new chapters on CRISPR cas-9, COVID-19, the biotechnology of cancer, and more |
| biotech vs life science: A Biotech Manager's Handbook M O'Neill, M M Hopkins, 2012-05-02 A biotech manager's handbook lays out - in a simple, straightforward manner - for the manager or would-be entrepreneur the basic principles of running a biotech company. Most managers in biotechnology companies are working in their first company or in their first managerial role. Their expertise and experience in the scientific part of the work can be taken as a given but there is a whole range of other skills to be learned and areas of expertise to come to terms with. Small companies do not have big budgets to hire people or time to become an expert in so many areas. The book starts by outlining the state of the biopharmaceutical industry and goes on to explain the importance of planning (no matter what the size of the company). Succeeding chapters deal with the basics of intellectual property, perspectives from a university technology transfer office and how to raise some initial funding from an investor and entrepreneur. - No other 'how to' manual exists for this sector - Written by a range of expert professionals in each area, all in one book - Is the only 'bench to bedside' book covering the whole spectrum of development |
| biotech vs life science: Industrialization of Biology National Research Council, Division on Earth and Life Studies, Board on Life Sciences, Board on Chemical Sciences and Technology, Committee on Industrialization of Biology: A Roadmap to Accelerate the Advanced Manufacturing of Chemicals, 2015-06-29 The tremendous progress in biology over the last half century - from Watson and Crick's elucidation of the structure of DNA to today's astonishing, rapid progress in the field of synthetic biology - has positioned us for significant innovation in chemical production. New bio-based chemicals, improved public health through improved drugs and diagnostics, and biofuels that reduce our dependency on oil are all results of research and innovation in the biological sciences. In the past decade, we have witnessed major advances made possible by biotechnology in areas such as rapid, low-cost DNA sequencing, metabolic engineering, and high-throughput screening. The manufacturing of chemicals using biological synthesis and engineering could expand even faster. A proactive strategy - implemented through the development of a technical roadmap similar to those that enabled sustained growth in the semiconductor industry and our explorations of space - is needed if we are to realize the widespread benefits of accelerating the industrialization of biology. Industrialization of Biology presents such a roadmap to achieve key technical milestones for chemical manufacturing through biological routes. This report examines the technical, economic, and societal factors that limit the adoption of bioprocessing in the chemical industry today and which, if surmounted, would markedly accelerate the advanced manufacturing of chemicals via industrial biotechnology. Working at the interface of synthetic chemistry, metabolic engineering, molecular biology, and synthetic biology, Industrialization of Biology identifies key technical goals for next-generation chemical manufacturing, then identifies the gaps in knowledge, tools, techniques, and systems required to meet those goals, and targets and timelines for achieving them. This report also considers the skills necessary to accomplish the roadmap goals, and what training opportunities are required to produce the cadre of skilled scientists and engineers needed. |
| biotech vs life science: Science Business Gary P. Pisano, 2006 Why has the biotechnology industry failed to perform up to expectations? This book attempts to answer this question by providing a critique of the industry. It reveals the causes of biotech's problems and offers an analysis on how the industry works. It also provides prescriptions for companies, seeking ways to improve the industry's performance. |
| biotech vs life science: Biochemical Engineering and Biotechnology Ghasem Najafpour, 2015-02-24 Biochemical Engineering and Biotechnology, 2nd Edition, outlines the principles of biochemical processes and explains their use in the manufacturing of every day products. The author uses a diirect approach that should be very useful for students in following the concepts and practical applications. This book is unique in having many solved problems, case studies, examples and demonstrations of detailed experiments, with simple design equations and required calculations. - Covers major concepts of biochemical engineering and biotechnology, including applications in bioprocesses, fermentation technologies, enzymatic processes, and membrane separations, amongst others - Accessible to chemical engineering students who need to both learn, and apply, biological knowledge in engineering principals - Includes solved problems, examples, and demonstrations of detailed experiments with simple design equations and all required calculations - Offers many graphs that present actual experimental data, figures, and tables, along with explanations |
| biotech vs life science: Valuation in Life Sciences Boris Bogdan, Ralph Villiger, 2010-04-19 Valuation is a hot topic among life sciences professionals. There is no clear understanding on how to use the different valuation approaches and how to determine input parameters. Some do not value at all, arguing that it is not possible to get realistic and objective numbers out of it. Some claim it to be an art. In the following chapters we will provide the user with a concise val- tion manual, providing transparency and practical insight for all dealing with valuation in life sciences: project and portfolio managers, licensing executives, business developers, technology transfer managers, entrep- neurs, investors, and analysts. The purpose of the book is to explain how to apply discounted cash flow and real options valuation to life sciences p- jects, i.e. to license contracts, patents, and firms. We explain the fun- mentals and the pitfalls with case studies so that the reader is capable of performing the valuations on his own and repeat the theory in the exercises and case studies. The book is structured in five parts: In the first part, the introduction, we discuss the role of the players in the life sciences industry and their p- ticular interests. We describe why valuation is important to them, where they need it, and the current problems to it. The second part deals with the input parameters required for valuation in life sciences, i.e. success rates, costs, peak sales, and timelines. |
| biotech vs life science: Introduction to Instrumentation in Life Sciences Prakash Singh Bisen, Anjana Sharma, 2012-09-26 Instrumentation is central to the study of physiology and genetics in living organisms, especially at the molecular level. Numerous techniques have been developed to address this in various biological disciplines, creating a need to understand the physical principles involved in the operation of research instruments and the parameters required in using them. Introduction to Instrumentation in Life Sciences fills this need by addressing different aspects of tools that hold the keys to cutting-edge research and innovative applications, from basic techniques to advanced instrumentation. The text describes all topics so even beginners can easily understand the theoretical and practical aspects. Comprehensive chapters encompass well-defined methodology that describes the instruments and their corresponding applications in different scientific fields. The book covers optical and electron microscopy; micrometry, especially in microbial taxonomy; pH meters and oxygen electrodes; chromatography for separation and purification of products from complex mixtures; spectroscopic and spectrophotometric techniques to determine structure and function of biomolecules; preparative and analytical centrifugation; electrophoretic techniques; x-ray microanalysis including crystallography; applications of radioactivity, including autoradiography and radioimmunoassays; and fermentation technology and subsequent separation of products of interest. The book is designed to serve a wide range of students and researchers in diversified fields of life sciences: pharmacy, biotechnology, microbiology, biochemistry, and environmental sciences. It introduces different aspects of basic experimental methods and instrumentation. The book is unique in its broad subject coverage, incorporating fundamental techniques as well as applications of modern molecular and proteomic tools that are the basis for state-of-the-art research. The text emphasizes techniques encountered both in practical classes and in high-throughput environments used in modern industry. As a further aid to students, the authors provide well-illustrated diagrams to explain the principles and theories behind the instruments described. |
| biotech vs life science: Putting Biotechnology to Work National Research Council, Division on Earth and Life Studies, Commission on Life Sciences, Committee on Bioprocess Engineering, 1992-02-01 The ability of the United States to sustain a dominant global position in biotechnology lies in maintaining its primacy in basic life-science research and developing a strong resource base for bioprocess engineering and bioproduct manufacturing. This book examines the status of bioprocessing and biotechnology in the United States; current bioprocess technology, products, and opportunities; and challenges of the future and what must be done to meet those challenges. It gives recommendations for action to provide suitable incentives to establish a national program in bioprocess-engineering research, development, education, and technology transfer. |
| biotech vs life science: Preparing for Future Products of Biotechnology National Academies of Sciences, Engineering, and Medicine, Division on Earth and Life Studies, Board on Chemical Sciences and Technology, Board on Agriculture and Natural Resources, Board on Life Sciences, Committee on Future Biotechnology Products and Opportunities to Enhance Capabilities of the Biotechnology Regulatory System, 2017-07-28 Between 1973 and 2016, the ways to manipulate DNA to endow new characteristics in an organism (that is, biotechnology) have advanced, enabling the development of products that were not previously possible. What will the likely future products of biotechnology be over the next 5â€10 years? What scientific capabilities, tools, and/or expertise may be needed by the regulatory agencies to ensure they make efficient and sound evaluations of the likely future products of biotechnology? Preparing for Future Products of Biotechnology analyzes the future landscape of biotechnology products and seeks to inform forthcoming policy making. This report identifies potential new risks and frameworks for risk assessment and areas in which the risks or lack of risks relating to the products of biotechnology are well understood. |
| biotech vs life science: The Business of Healthcare Innovation Lawton Robert Burns, 2005-08-25 The Business of Healthcare Innovation is the first wide-ranging analysis of business trends in the manufacturing segment of the health care industry. In this leading edge volume, Professor Burns focuses on the key role of the 'producers' as the main source of innovation in health systems. Written by professors of the Wharton School and industry executives, this book provides a detailed overview of the pharmaceutical, biotechnology, genomics/proteomics, medical device and information technology sectors. It analyses the market structures of these sectors as well as the business models and corporate strategies of firms operating within them. Most importantly, the book describes the growing convergence between these sectors and the need for executives in one sector to increasingly draw upon trends in the others. It will be essential reading for students and researchers in the field of health management, and of great interest to strategy scholars, industry practitioners and management consultants. |
| biotech vs life science: Biotechnology Entrepreneurship Craig Shimasaki, 2014-04-08 As an authoritative guide to biotechnology enterprise and entrepreneurship, Biotechnology Entrepreneurship and Management supports the international community in training the biotechnology leaders of tomorrow. Outlining fundamental concepts vital to graduate students and practitioners entering the biotech industry in management or in any entrepreneurial capacity, Biotechnology Entrepreneurship and Management provides tested strategies and hard-won lessons from a leading board of educators and practitioners. It provides a 'how-to' for individuals training at any level for the biotech industry, from macro to micro. Coverage ranges from the initial challenge of translating a technology idea into a working business case, through securing angel investment, and in managing all aspects of the result: business valuation, business development, partnering, biological manufacturing, FDA approvals and regulatory requirements. An engaging and user-friendly style is complemented by diverse diagrams, graphics and business flow charts with decision trees to support effective management and decision making. - Provides tested strategies and lessons in an engaging and user-friendly style supplemented by tailored pedagogy, training tips and overview sidebars - Case studies are interspersed throughout each chapter to support key concepts and best practices. - Enhanced by use of numerous detailed graphics, tables and flow charts |
| biotech vs life science: The Life Science Executive's Fundraising Manifesto Dennis Ford, 2014-07-01 A primary objective for life science executives is raising capital. Very often, however, a lack of marketing and sales skills impedes their efforts. Focusing regionally, rather than globally, only compounds the challenge. The Life Science Executive's Fundraising Manifesto helps scientists understand the fundamental skills needed to brand and market their companies. It discusses how to use a consistent message to achieve compelling results from a fundraising campaign, and it teaches you how to aggregate a list of potential global investors that are a fit for your company's products and services. The book also explains how to efficiently and effectively reach out to potential investor targets, start a dialogue that fosters a relationship, and ultimately secure capital allocations. Raising capital is not a one-time event. It must be an ongoing part of your business strategy. This book reveals the expertise required to continually fundraise and bring your ideas to market. For more information about the book, please visit www.fundraisingmanifesto.com. |
| biotech vs life science: Life as Surplus Melinda E. Cooper, 2011-02-01 Focusing on the period between the 1970s and the present, Life as Surplus is a pointed and important study of the relationship between politics, economics, science, and cultural values in the United States today. Melinda Cooper demonstrates that the history of biotechnology cannot be understood without taking into account the simultaneous rise of neoliberalism as a political force and an economic policy. From the development of recombinant DNA technology in the 1970s to the second Bush administration's policies on stem cell research, Cooper connects the utopian polemic of free-market capitalism with growing internal contradictions of the commercialized life sciences. The biotech revolution relocated economic production at the genetic, microbial, and cellular level. Taking as her point of departure the assumption that life has been drawn into the circuits of value creation, Cooper underscores the relations between scientific, economic, political, and social practices. In penetrating analyses of Reagan-era science policy, the militarization of the life sciences, HIV politics, pharmaceutical imperialism, tissue engineering, stem cell science, and the pro-life movement, the author examines the speculative impulses that have animated the growth of the bioeconomy. At the very core of the new post-industrial economy is the transformation of biological life into surplus value. Life as Surplus offers a clear assessment of both the transformative, therapeutic dimensions of the contemporary life sciences and the violence, obligation, and debt servitude crystallizing around the emerging bioeconomy. |
| biotech vs life science: Opportunities in Biotechnology for Future Army Applications National Research Council, Division on Engineering and Physical Sciences, Board on Army Science and Technology, Committee on Opportunities in Biotechnology for Future Army Applications, 2001-07-11 This report surveys opportunities for future Army applications in biotechnology, including sensors, electronics and computers, materials, logistics, and medical therapeutics, by matching commercial trends and developments with enduring Army requirements. Several biotechnology areas are identified as important for the Army to exploit, either by direct funding of research or by indirect influence of commercial sources, to achieve significant gains in combat effectiveness before 2025. |
| biotech vs life science: Biosecurity in Putin's Russia Raymond A. Zilinskas, Philippe Mauger, 2018 |
| biotech vs life science: Biotechnology in Medical Sciences Firdos Alam Khan, 2014-05-08 As the field of medical biotechnology grows with new products and discoveries, so does the need for a holistic view of biotechnology in medicine. Biotechnology in Medical Sciences fulfills that need by delivering a detailed overview of medical biotechnology as it relates to human diseases and epidemiology, bacteriology and antibiotics, virology and vaccines, immunology and monoclonal antibodies, recombinant DNA technology and therapeutic proteins, stem cell technology, tissue engineering, molecular diagnostics and forensic science, gene therapy, synthetic biology and nanomedicine, pharmacogenomics, bioethics, biobusiness and intellectual property rights, and career opportunities. Organized to follow the chronology of major medical biotechnology research, breakthroughs, and events, this first-of-its-kind text: Covers all aspects of medical biotechnology, from labs to clinics and basic to advanced applications Describes historical perspectives and modern discoveries in medical biotechnology Explains how various biotechnology products are used to treat and prevent disease Discusses the tools and techniques currently employed in medical biotechnology Includes a bibliography at the end of each chapter to encourage further study Complete with colorful illustrations and examples, Biotechnology in Medical Sciences provides a comprehensive yet accessible treatment of this growing field. |
| biotech vs life science: Academia to Biotechnology Jeffrey M Gimble, 2004-10-08 Academia to Biotechnology deals with both the abstract and practical aspects of moving from a univerisity laboratory to a position in the biotech industry. Each chapter lists common and unique features to evaluate breaking down complex decisions into manageable elements. Several sections provide how to guides for the preparation of manuscripts, patents, grants, and internal company documents. - Written by an experienced academician and successful biotechnology entrepreneur - Reviews the basic tools taught in a traditional university - Identifies new ways these these tools will be used in the corporate world - Details the 'nuts and bolts' necessary to negotiate a successful position in the biotech industry |
| biotech vs life science: Basic Biotechnology Colin Ratledge, Bjorn Kristiansen, 2006-05-25 Biotechnology is one of the major technologies of the twenty-first century. Its wide-ranging, multi-disciplinary activities include recombinant DNA techniques, cloning and the application of microbiology to the production of goods from bread to antibiotics. In this new edition of the textbook Basic Biotechnology, biology and bioprocessing topics are uniquely combined to provide a complete overview of biotechnology. The fundamental principles that underpin all biotechnology are explained and a full range of examples are discussed to show how these principles are applied; from starting substrate to final product. A distinctive feature of this text are the discussions of the public perception of biotechnology and the business of biotechnology, which set the science in a broader context. This comprehensive textbook is essential reading for all students of biotechnology and applied microbiology, and for researchers in biotechnology industries. |
| biotech vs life science: The Billion-Dollar Molecule Barry Werth, 2013-08-20 Join journalist Barry Werth as he pulls back the curtain on Vertex, a start-up pharmaceutical company, and witness firsthand the intense drama being played out in the pioneering and hugely profitable field of drug research. Founded by Joshua Boger, a dynamic Harvard- and Merck-trained scientific whiz kid, Vertex is dedicated to designing—atom by atom—both a new life-saving immunosuppressant drug, and a drug to combat the virus that causes AIDS. You will be hooked from start to finish, as you go from the labs, where obsessive, fiercely competitive scientists struggle for a breakthrough, to Wall Street, where the wheeling and dealing takes on a life of its own, as Boger courts investors and finally decides to take Vertex public. Here is a fascinating no-holds-barred account of the business of science, which includes an updated epilogue about the most recent developments in the quest for a drug to cure AIDS. |
| biotech vs life science: Biotechnology Research in an Age of Terrorism National Research Council, Policy and Global Affairs, Development, Security, and Cooperation, Committee on Research Standards and Practices to Prevent the Destructive Application of Biotechnology, 2004-03-02 In recent years much has happened to justify an examination of biological research in light of national security concerns. The destructive application of biotechnology research includes activities such as spreading common pathogens or transforming them into even more lethal forms. Policymakers and the scientific community at large must put forth a vigorous and immediate response to this challenge. This new book by the National Research Council recommends that the government expand existing regulations and rely on self-governance by scientists rather than adopt intrusive new policies. One key recommendation of the report is that the government should not attempt to regulate scientific publishing but should trust scientists and journals to screen their papers for security risks, a task some journals have already taken up. With biological information and tools widely distributed, regulating only U.S. researchers would have little effect. A new International Forum on Biosecurity should encourage the adoption of similar measures around the world. Seven types of risky studies would require approval by the Institutional Biosafety Committees that already oversee recombinant DNA research at some 400 U.S. institutions. These experiments of concern include making an infectious agent more lethal and rendering vaccines powerless. |
| biotech vs life science: The Business of Bioscience Craig D. Shimasaki, 2009-09-18 My journey into this fascinating field of biotechnology started about 26 years ago at a small biotechnology company in South San Francisco called Genentech. I was very fortunate to work for the company that begat the biotech industry during its formative years. This experience established a solid foundation from which I could grow in both the science and business of biotechnology. After my fourth year of working on Oyster Point Boulevard, a close friend and colleague left Genentech to join a start-up biotechnology company. Later, he approached me to leave and join him in of all places – Oklahoma. He persisted for at least a year before I seriously considered his proposal. After listening to their plans, the opportunity suddenly became more and more intriguing. Finally, I took the plunge and joined this ent- preneurial team in cofounding and growing a start-up biotechnology company. Making that fateful decision to leave the security of a larger company was extremely difficult, but it turned out to be the beginning of an entrepreneurial career that forever changed how I viewed the biotechnology industry. Since that time, I have been fortunate to have cofounded two other biotechnology com- nies and even participated in taking one of them public. During my career in these start-ups, I held a variety of positions, from directing the science, operations, regulatory, and marketing components, to subsequently becoming CEO. |
| biotech vs life science: An Introduction to Biotechnology W.T. Godbey, 2014-12-08 An Introduction to Biotechnology is a biotechnology textbook aimed at undergraduates. It covers the basics of cell biology, biochemistry and molecular biology, and introduces laboratory techniques specific to the technologies addressed in the book; it addresses specific biotechnologies at both the theoretical and application levels.Biotechnology is a field that encompasses both basic science and engineering. There are currently few, if any, biotechnology textbooks that adequately address both areas. Engineering books are equation-heavy and are written in a manner that is very difficult for the non-engineer to understand. Numerous other attempts to present biotechnology are written in a flowery manner with little substance. The author holds one of the first PhDs granted in both biosciences and bioengineering. He is more than an author enamoured with the wow-factor associated with biotechnology; he is a practicing researcher in gene therapy, cell/tissue engineering, and other areas and has been involved with emerging technologies for over a decade. Having made the assertion that there is no acceptable text for teaching a course to introduce biotechnology to both scientists and engineers, the author committed himself to resolving the issue by writing his own. - The book is of interest to a wide audience because it includes the necessary background for understanding how a technology works. - Engineering principles are addressed, but in such a way that an instructor can skip the sections without hurting course content - The author has been involved with many biotechnologies through his own direct research experiences. The text is more than a compendium of information - it is an integrated work written by an author who has experienced first-hand the nuances associated with many of the major biotechnologies of general interest today. |
| biotech vs life science: Emerging Consequences of Biotechnology Krishna R. Dronamraju, 2008 The principal message of this book is that thermodynamics and statistical mechanics will benefit from replacing the unfortunate, misleading and mysterious term entropy with a more familiar, meaningful and appropriate term such as information, missing information or uncertainty. This replacement would facilitate the interpretation of the driving force of many processes in terms of informational changes and dispel the mystery that has always enshrouded entropy. It has been 140 years since Clausius coined the term entropy; almost 50 years since Shannon developed the mathematical theory of information--Subsequently renamed entropy. In this book, the author advocates replacing entropy by information, a term that has become widely used in many branches of science. The author also takes a new and bold approach to thermodynamics and statistical mechanics. Information is used not only as a tool for predicting distributions but as the fundamental cornerstone concept of thermodynamics, held until now by the term entropy. The topics covered include the fundamentals of probability and information theory; the general concept of information as well as the particular concept of information as applied in thermodynamics; the re-derivation of the Sackur-Tetrode equation for the entropy of an ideal gas from purely informational arguments; the fundamental formalism of statistical mechanics; and many examples of simple processes the driving force for which is analyzed in terms of information. |
| biotech vs life science: Biotechnology in the Chemical Industry Pratima Bajpai, 2019-11-08 Biotechnology in the Chemical Industry: Towards a Green and Sustainable Future focuses on achievements and prospects for biotechnology in sustainable production of goods and services, especially those that are derived at present mostly from the traditional chemical industry. It considers the future impact of industrial biotechnology and lays out the major research areas which must be addressed to move from a flourishing set of scientific disciplines to a major contributor to a successful future knowledge-based economy. The book focuses on the research needed to underpin three broad topics: biomass, bio-processes and bio-products, including bio-energy. Readers, including advanced students, researchers, industry professionals, academics, analysts, consultants, and anyone else interested, or involved in biotechnology will find this book very informative. - Offers a comprehensive introduction to the subject for researchers interested in the biotechnological applications in chemical industry - Provides a state-of-the art update on the field - Presents the economic and ecological advantages of industrial biotechnology - Discusses efforts made by developing countries towards industrial biotechnology - Describes new biotechnological applications - Includes the major challenges facing industrial biotechnology |
| biotech vs life science: Modern Applications of Plant Biotechnology in Pharmaceutical Sciences Saurabh Bhatia, Kiran Sharma, Randhir Dahiya, Tanmoy Bera, 2015-07-22 Modern Applications of Plant Biotechnology in Pharmaceutical Sciences explores advanced techniques in plant biotechnology, their applications to pharmaceutical sciences, and how these methods can lead to more effective, safe, and affordable drugs. The book covers modern approaches in a practical, step-by-step manner, and includes illustrations, examples, and case studies to enhance understanding. Key topics include plant-made pharmaceuticals, classical and non-classical techniques for secondary metabolite production in plant cell culture and their relevance to pharmaceutical science, edible vaccines, novel delivery systems for plant-based products, international industry regulatory guidelines, and more. Readers will find the book to be a comprehensive and valuable resource for the study of modern plant biotechnology approaches and their pharmaceutical applications. - Builds upon the basic concepts of cell and plant tissue culture and recombinant DNA technology to better illustrate the modern and potential applications of plant biotechnology to the pharmaceutical sciences - Provides detailed yet practical coverage of complex techniques, such as micropropogation, gene transfer, and biosynthesis - Examines critical issues of international importance and offers real-life examples and potential solutions |
| biotech vs life science: Business Modeling for Life Science and Biotech Companies Alberto Onetti, Antonella Zucchella, 2014-03-21 Most books on the biotechnology industry focus on scientific and technological challenges, ignoring the entrepreneurial and managerial complexities faced bio-entrepreneurs. The Business Models for Life Science Firms aims to fill this gap by offering managers in this rapid growth industry the tools needed to design and implement an effective business model customized for the unique needs of research intensive organizations. Onetti and Zucchella begin by unpacking the often-used ‘business model’ term, examining key elements of business model conceptualization and offering a three tier approach with a clear separation between the business model and strategy: focus, exploring the different activities carried out by the organization; locus, evaluating where organizational activities are centered; and modus, testing the execution of the organization’s activities. The business model thus defines the unique way in which a company delivers on its promise to its customers. The theory and applications adopt a global approach, offering business cases from a variety of biotech companies around the world. |
| biotech vs life science: Science Lessons Gordon M. Binder, Philip Bashe, 2008 Under Gordon Binder's leadership, Amgen became the world's largest and most successful biotech company in the world. This text describes what it really takes to manage risk, financing, creative employees, and intellectual property on the international stage. |
| biotech vs life science: Machine Learning in Biotechnology and Life Sciences Saleh Alkhalifa, 2022-01-28 Explore all the tools and templates needed for data scientists to drive success in their biotechnology careers with this comprehensive guide Key FeaturesLearn the applications of machine learning in biotechnology and life science sectorsDiscover exciting real-world applications of deep learning and natural language processingUnderstand the general process of deploying models to cloud platforms such as AWS and GCPBook Description The booming fields of biotechnology and life sciences have seen drastic changes over the last few years. With competition growing in every corner, companies around the globe are looking to data-driven methods such as machine learning to optimize processes and reduce costs. This book helps lab scientists, engineers, and managers to develop a data scientist's mindset by taking a hands-on approach to learning about the applications of machine learning to increase productivity and efficiency in no time. You'll start with a crash course in Python, SQL, and data science to develop and tune sophisticated models from scratch to automate processes and make predictions in the biotechnology and life sciences domain. As you advance, the book covers a number of advanced techniques in machine learning, deep learning, and natural language processing using real-world data. By the end of this machine learning book, you'll be able to build and deploy your own machine learning models to automate processes and make predictions using AWS and GCP. What you will learnGet started with Python programming and Structured Query Language (SQL)Develop a machine learning predictive model from scratch using PythonFine-tune deep learning models to optimize their performance for various tasksFind out how to deploy, evaluate, and monitor a model in the cloudUnderstand how to apply advanced techniques to real-world dataDiscover how to use key deep learning methods such as LSTMs and transformersWho this book is for This book is for data scientists and scientific professionals looking to transcend to the biotechnology domain. Scientific professionals who are already established within the pharmaceutical and biotechnology sectors will find this book useful. A basic understanding of Python programming and beginner-level background in data science conjunction is needed to get the most out of this book. |
| biotech vs life science: Biotechnology and Biochemical Engineering Prasanna B. D., Sathyanarayana N Gummadi, Praveen V. Vadlani, 2016-09-20 This book serves to highlight the seamless integration of the sciences leading to sustainable technologies. Chemical engineering is one of the major disciplines catering to the societal needs in the fields of energy, environment and materials. The chapters of this book have been selected to encompass the latest in industrial biotechnology and biochemical engineering principles and applications. The chapters are included here after careful review for content and depth. The book focuses on the relatively new areas of molecular biotechnology and nanotechnology which have a strong impact at the fundamental and process levels in chemical engineering. The book also covers analytical procedures, experimental techniques and process analysis in bioprocessing, bioremediation, green separation methods, and emerging nanoparticle applications. It should be useful to students, academicians, and practitioners alike. |
| biotech vs life science: Pharmaceutical Biotechnology Daan J. A. Crommelin, Robert D. Sindelar, 2002-11-14 The field of pharmaceutical biotechnology is evolving rapidly. A whole new arsenal of protein pharmaceuticals is being produced by recombinant techniques for cancer, viral infections, cardiovascular and hereditary disorders, and other diseases. In addition, scientists are confronted with new technologies such as polymerase chain reactions, combinatorial chemistry and gene therapy. This introductory textbook provides extensive coverage of both the basic science and the applications of biotechnology-produced pharmaceuticals, with special emphasis on their clinical use. Pharmaceutical Biotechnology serves as a complete one-stop source for undergraduate pharmacists, and it is valuable for researchers and professionals in the pharmaceutical industry as well. |
Biopharma Trends 2025
based on innovative science and new modalities are emerging faster than ever. Intensifying competition, declining R&D productivity, payer pressures, and a steep patent cliff are testing …
Biotechnology, Medical Device, and Other Life Sciences …
• Life Sciences industry composed of several different sectors, including biopharmaceuticals, medical devices, diagnostics, research tools, and biomedical materials • Each sector of the life …
Sector profile: Life Sciences and Biotech - LLEP
Major trends that existed before the Covid-19 pandemic, will continue, and have a massive impact on life sciences and biotechnology. The global population continues to age – with the …
LEADING LIFE SCIENCE CLUSTERS - Greater Houston Partnership
While life science employment was down by just 1.3% in July from its peak in March, it was 1% higher than a year ago compared with the 7.6% decline in total nonfarm employment. Biotech …
Life Sciences Industry Accounting Guide Revenue Recognition
The life sciences ecosystem encompasses a wide array of entities that discover, develop, and manufacture health care products. Such entities include pharmaceutical manufacturers; …
Why Biomedical Science and Biotechnology? - University of …
for other benefits to humans or animals. It combines traditional science with aspects of engineering and computer scien. works and what happens when it doesn’t. It focuses on areas …
Life Sciences Practice Vision 2028: How China could impact …
Life Sciences Practice Vision 2028: How China could impact the global biopharma industry Biopharmas originating in China will likely have greater influence on the industry by 2028, but …
REVENUE, R&D AND BIOTECH’S FUTURE - BDO USA
In September 2020, BDO’s Biotech Brief found that R&D spending was outpacing revenue. But in 2021, that trend has started to reverse for medium and large companies, although small …
Technology Readiness Level scale in Life Sciences & Health
Basic technological components are integrated to establish that they will work together. This is relatively ‘low fidelity’ compared with eventual system. Analytical studies to predict …
Biotech Vs Life Science (Download Only) - old.icapgen.org
The biotech arena emerged in the 1970s and 1980s when molecular biology one of the fastest moving areas of basic science in the twentieth century met the business world Gene Jockeys …
Life science trend analysis | 2020 - biotechgate.com
Biotech companies are a subset of Life Science companies and include: Biotech - Therapeutic and Diagnostic, Biotech - R&D Services, Biotech – Others. Financing data only incl. private …
BIOSCIENCE AND HEALTH TECHNOLOGY SECTOR STATISTICS …
The UK life sciences industry employs 248,400 people in 5,8701 businesses and generates a turnover of £73.8bn. The Core Biopharma and Core Med Tech sectors contain businesses …
How will smaller, smarter deals help life sciences companies …
In 2024, life sciences companies pivoted away from large-scale M&A deals looking for smaller, smarter deals. The 2025 edition of the EY M&A Firepower report finds the industry widening …
Initial Public Offerings: Life Science (Biotech and Pharma) IPOs ...
Life science includes biotech and pharmaceutical firms. Life science is defined as SIC=2830, 2834, 2835, 2836, and 8731. In prior years, I had included 2833 (medical chemicals and …
Index Advisory The relative importance of Biotech versus Broa
Biotech indices have helped focus attention on the sector and have led to the creation of successful investment products such as the iShares Biotechnology ETF (IBB). As of March …
How to Approach Asset Valuation in Pharma & Biotech
There are a number of ways to value an asset in the life sciences space, with many additional nuances to consider. The selection of one method over another is often inluenced by a …
Advanced Biopharmaceutical Manufacturing: An Evolution …
Biopharmaceutical manufacturing is generally characterized by the use of advanced technologies, harnessing of new scientific advances, and driven by a highly complex research and …
SECTOR REPORT 2022 BIOTECH & LIFESCIENCES - ICICI …
15% for one year infused new energy to biotech startups in 2022. Despite geopolitical concerns, India continued to supply generic medicines to 200 countries. India’s association with QUAD …
texas biotechnology & life sciences
Texas’ highly trained workforce, top-tier research institu-tions and business-friendly climate position the state as a global life sciences powerhouse. Home to more than 6,100 …
HOW TO BECOME A PATENT ANALYST IN LIFE SCIENCES
Despite the explosive demand for IP protection in biotech, pharma, and life science industries, many graduates are unaware that their degrees hold the key to a high-income, flexible, and …
Biopharma Trends 2025
based on innovative science and new modalities are emerging faster than ever. Intensifying competition, declining R&D productivity, payer pressures, and a steep patent cliff are testing …
Biotechnology, Medical Device, and Other Life Sciences …
• Life Sciences industry composed of several different sectors, including biopharmaceuticals, medical devices, diagnostics, research tools, and biomedical materials • Each sector of the life …
Sector profile: Life Sciences and Biotech - LLEP
Major trends that existed before the Covid-19 pandemic, will continue, and have a massive impact on life sciences and biotechnology. The global population continues to age – with the …
LEADING LIFE SCIENCE CLUSTERS - Greater Houston …
While life science employment was down by just 1.3% in July from its peak in March, it was 1% higher than a year ago compared with the 7.6% decline in total nonfarm employment. Biotech …
Life Sciences Industry Accounting Guide Revenue Recognition
The life sciences ecosystem encompasses a wide array of entities that discover, develop, and manufacture health care products. Such entities include pharmaceutical manufacturers; …
Why Biomedical Science and Biotechnology? - University of …
for other benefits to humans or animals. It combines traditional science with aspects of engineering and computer scien. works and what happens when it doesn’t. It focuses on areas …
Life Sciences Practice Vision 2028: How China could impact …
Life Sciences Practice Vision 2028: How China could impact the global biopharma industry Biopharmas originating in China will likely have greater influence on the industry by 2028, but …
REVENUE, R&D AND BIOTECH’S FUTURE - BDO USA
In September 2020, BDO’s Biotech Brief found that R&D spending was outpacing revenue. But in 2021, that trend has started to reverse for medium and large companies, although small …
Technology Readiness Level scale in Life Sciences & Health …
Basic technological components are integrated to establish that they will work together. This is relatively ‘low fidelity’ compared with eventual system. Analytical studies to predict …
Biotech Vs Life Science (Download Only) - old.icapgen.org
The biotech arena emerged in the 1970s and 1980s when molecular biology one of the fastest moving areas of basic science in the twentieth century met the business world Gene Jockeys …
Life science trend analysis | 2020 - biotechgate.com
Biotech companies are a subset of Life Science companies and include: Biotech - Therapeutic and Diagnostic, Biotech - R&D Services, Biotech – Others. Financing data only incl. private …
BIOSCIENCE AND HEALTH TECHNOLOGY SECTOR …
The UK life sciences industry employs 248,400 people in 5,8701 businesses and generates a turnover of £73.8bn. The Core Biopharma and Core Med Tech sectors contain businesses …
How will smaller, smarter deals help life sciences companies …
In 2024, life sciences companies pivoted away from large-scale M&A deals looking for smaller, smarter deals. The 2025 edition of the EY M&A Firepower report finds the industry widening …
Initial Public Offerings: Life Science (Biotech and Pharma) …
Life science includes biotech and pharmaceutical firms. Life science is defined as SIC=2830, 2834, 2835, 2836, and 8731. In prior years, I had included 2833 (medical chemicals and …
Index Advisory The relative importance of Biotech versus Broa
Biotech indices have helped focus attention on the sector and have led to the creation of successful investment products such as the iShares Biotechnology ETF (IBB). As of March …
How to Approach Asset Valuation in Pharma & Biotech
There are a number of ways to value an asset in the life sciences space, with many additional nuances to consider. The selection of one method over another is often inluenced by a …
Advanced Biopharmaceutical Manufacturing: An Evolution …
Biopharmaceutical manufacturing is generally characterized by the use of advanced technologies, harnessing of new scientific advances, and driven by a highly complex research and …
SECTOR REPORT 2022 BIOTECH & LIFESCIENCES
15% for one year infused new energy to biotech startups in 2022. Despite geopolitical concerns, India continued to supply generic medicines to 200 countries. India’s association with QUAD …
texas biotechnology & life sciences
Texas’ highly trained workforce, top-tier research institu-tions and business-friendly climate position the state as a global life sciences powerhouse. Home to more than 6,100 …
HOW TO BECOME A PATENT ANALYST IN LIFE SCIENCES
Despite the explosive demand for IP protection in biotech, pharma, and life science industries, many graduates are unaware that their degrees hold the key to a high-income, flexible, and …
